A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease

J C Mansfield; M Parkes; A B Hawthorne; A Forbes; C S J Probert; R C Perowne; A Cooper; J B Zeldis; D C Manning; C J Hawkey

doi:10.1111/j.1365-2036.2007.03385.x

A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease

J C Mansfield, M Parkes, A B Hawthorne, A Forbes, C S J Probert, R C Perowne, A Cooper, J B Zeldis, D C Manning, C J Hawkey

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Abstract

Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease.

Original language	English
Pages (from-to)	421-430
Number of pages	10
Journal	Alimentary Pharmacology and Therapeutics
Volume	26
Issue number	3
DOIs	https://doi.org/10.1111/j.1365-2036.2007.03385.x
Publication status	Published - 1 Aug 2007

Keywords

Adolescent
Adult
Aged
Crohn Disease
Double-Blind Method
Female
Humans
Immunosuppressive Agents
Male
Middle Aged
Placebos
Severity of Illness Index
Thalidomide
Treatment Outcome
Venous Thrombosis

Access to Document

10.1111/j.1365-2036.2007.03385.x

Cite this

Mansfield, J. C., Parkes, M., Hawthorne, A. B., Forbes, A., Probert, C. S. J., Perowne, R. C., Cooper, A., Zeldis, J. B., Manning, D. C., & Hawkey, C. J. (2007). A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Alimentary Pharmacology and Therapeutics, 26(3), 421-430. https://doi.org/10.1111/j.1365-2036.2007.03385.x

@article{972b80b46e7c449db401f55fc6aca744,

title = "A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease",

abstract = "Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease.",

keywords = "Adolescent, Adult, Aged, Crohn Disease, Double-Blind Method, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Placebos, Severity of Illness Index, Thalidomide, Treatment Outcome, Venous Thrombosis",

author = "Mansfield, {J C} and M Parkes and Hawthorne, {A B} and A Forbes and Probert, {C S J} and Perowne, {R C} and A Cooper and Zeldis, {J B} and Manning, {D C} and Hawkey, {C J}",

year = "2007",

month = aug,

day = "1",

doi = "10.1111/j.1365-2036.2007.03385.x",

language = "English",

volume = "26",

pages = "421--430",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "Wiley",

number = "3",

}

Mansfield, JC, Parkes, M, Hawthorne, AB, Forbes, A, Probert, CSJ, Perowne, RC, Cooper, A, Zeldis, JB, Manning, DC & Hawkey, CJ 2007, 'A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease', Alimentary Pharmacology and Therapeutics, vol. 26, no. 3, pp. 421-430. https://doi.org/10.1111/j.1365-2036.2007.03385.x

A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. / Mansfield, J C; Parkes, M; Hawthorne, A B; Forbes, A; Probert, C S J; Perowne, R C; Cooper, A; Zeldis, J B; Manning, D C; Hawkey, C J.

In: Alimentary Pharmacology and Therapeutics, Vol. 26, No. 3, 01.08.2007, p. 421-430.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease

AU - Mansfield, J C

AU - Parkes, M

AU - Hawthorne, A B

AU - Forbes, A

AU - Probert, C S J

AU - Perowne, R C

AU - Cooper, A

AU - Zeldis, J B

AU - Manning, D C

AU - Hawkey, C J

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease.

AB - Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease.

KW - Adolescent

KW - Adult

KW - Aged

KW - Crohn Disease

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Immunosuppressive Agents

KW - Male

KW - Middle Aged

KW - Placebos

KW - Severity of Illness Index

KW - Thalidomide

KW - Treatment Outcome

KW - Venous Thrombosis

U2 - 10.1111/j.1365-2036.2007.03385.x

DO - 10.1111/j.1365-2036.2007.03385.x

M3 - Article

C2 - 17635377

VL - 26

SP - 421

EP - 430

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 3

ER -